Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1-10. (canceled)

11. (previously presented) A transmucosal drug delivery device having a composition comprising:

- a polymeric resin;
- a linear elastomeric polymer;
- a cross-linked elastomeric polymer being 30-80% cross-linked; and
- a pharmacological agent,

wherein the ratio of linear elastomeric polymer to cross-linked elastomeric polymer is about 1:2 to 5:1.

12. (canceled)

13. (original) A transmucosal drug delivery device according to claim 11 wherein:

(i) the polymeric resin is a particular polymeric resin present in an amount of from about 40 to about 65 percent by weight based on the total weight of the composition;

(ii) the linear elastomeric polymer is present in an amount of from about 15 to about 50 percent by weight based on the total weight of the composition; and

(iii) the cross-linked elastomeric poly is present in an amount of from about 5 to about 30 percent by weight based on the total weight of the composition.

14. (original) The transmucosal drug delivery device according to claim 13 wherein the particulate polymeric resin is a linear polyacrylic acid resin.

15. (original) The transmucosal drug delivery device according to claim 13 wherein the linear elastomeric polymer is selected from the group consisting of polyisobutylene, polyisoprene and mixtures thereof

16. (original) The transmucosal drug delivery device according to claim 13 wherein the cross-linked elastomeric polymer is a cross-linked butyl terpolymer rubber.

17. (original) The transmucosal drug delivery device according to claim 13 further comprising a penetration enhancer.

18. (previously presented) The transmucosal drug delivery device according to claim 11 wherein the pharmacological agent is selected from the group consisting of detomidine, medetomidine, dexmedetomidine, atapamazole, fentanyl, ketamine and pharmaceutically acceptably salts thereof.

19. (original) The transmucosal drug delivery device according to claim 17 wherein the pharmacological agent is present in an amount of from about 2 to about 5 percent by weight based on the total weight of the composition and the pharmacological agent is selected from the group consisting of medetomidine, dexmedetomidine and pharmaceutically acceptable salts thereof; and glycerol monolaurate is present in an amount of from about 0.5 to 5 percent by weight based on the total weight of the composition.

20. (original) The transmucosal drug delivery device according to claim 11 wherein the pharmacological agent is present in an amount from about 0.5 to about 10 percent based on the total weight of the composition.

21-22. (canceled)